Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 1/2011

01-03-2011 | Original Paper

Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms

Authors: Suraj Kachgal, Andrew J. Putnam

Published in: Angiogenesis | Issue 1/2011

Login to get access

Abstract

Using a fibrin-based angiogenesis model, we have established that there is no canonical mechanism used by endothelial cells (ECs) to degrade the surrounding extracellular matrix (ECM), but rather the set of proteases used is dependent on the mural cells providing the angiogenic cues. Mesenchymal stem cells (MSCs) originating from different tissues, which are thought to be phenotypically similar, promote angiogenesis through distinct mechanisms. Specifically, adipose-derived stem cells (ASCs) promote utilization of the plasminogen activator-plasmin axis by ECs as the primary means of vessel invasion and elongation in fibrin. Matrix metalloproteinases (MMPs) serve a purpose in regulating capillary diameter and possibly in stabilizing the nascent vessels. These proteolytic mechanisms are more akin to those involved in fibroblast-mediated angiogenesis than to those in bone marrow-derived stem cell (BMSC)-mediated angiogenesis. In addition, expression patterns of angiogenic factors such as urokinase plasminogen activator (uPA), hepatocyte growth factor (HGF), and tumor necrosis factor alpha (TNFα) were similar for ASC and fibroblast-mediated angiogenesis, and in direct contrast to BMSC-mediated angiogenesis. The present study illustrates that the nature of the heterotypic interactions between mural cells and endothelial cells depend on the identity of the mural cell used. Even MSCs which are shown to behave phenotypically similar do not stimulate angiogenesis via the same mechanisms.
Literature
1.
2.
3.
Griffith CK et al (2005) Diffusion limits of an in vitro thick prevascularized tissue. Tissue Eng 11(1–2):257–266CrossRefPubMed
4.
Fuchs S et al (2001) Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J Am Coll Cardiol 37(6):1726–1732CrossRefPubMed
5.
Rehman J et al (2004) Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 109(10):1292–1298CrossRefPubMed
6.
Ghajar CM, George SC, Putnam AJ (2008) Matrix metalloproteinase control of capillary morphogenesis. Crit Rev Eukaryot Gene Expr 18(3):251–278PubMed
7.
Kroon ME et al (1999) Role and localization of urokinase receptor in the formation of new microvascular structures in fibrin matrices. Am J Pathol 154(6):1731–1742CrossRefPubMed
8.
Kroon ME et al (2000) Urokinase receptor expression on human microvascular endothelial cells is increased by hypoxia: implications for capillary-like tube formation in a fibrin matrix. Blood 96(8):2775–2783PubMed
9.
Kroon ME et al (2001) Vascular endothelial growth factor enhances the expression of urokinase receptor in human endothelial cells via protein kinase C activation. Thromb Haemost 85(2):296–302PubMed
10.
Chun TH et al (2004) MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 167(4):757–767CrossRefPubMed
11.
Hotary KB et al (2002) Matrix metalloproteinases (MMPs) regulate fibrin-invasive activity via MT1-MMP-dependent and -independent processes. J Exp Med 195(3):295–308CrossRefPubMed
12.
Yancopoulos GD et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242–248CrossRefPubMed
13.
Ghajar CM et al (2010) Mesenchymal cells stimulate capillary morphogenesis via distinct proteolytic mechanisms. Exp Cell Res 316(5):813–825CrossRefPubMed
14.
Crisan M et al (2008) A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3(3):301–313CrossRefPubMed
15.
16.
17.
Nakatsu MN, Hughes CC (2008) An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol 443:65–82CrossRefPubMed
18.
Ghajar CM et al (2006) Mesenchymal stem cells enhance angiogenesis in mechanically viable prevascularized tissues via early matrix metalloproteinase upregulation. Tissue Eng 12(10):2875–2888CrossRefPubMed
19.
Ghajar CM et al (2008) The effect of matrix density on the regulation of 3-D capillary morphogenesis. Biophys J 94(5):1930–1941CrossRefPubMed
20.
Zuk PA et al (2001) Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7(2):211–228CrossRefPubMed
21.
Galvez BG et al (2001) Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling. J Biol Chem 276(40):37491–37500CrossRefPubMed
22.
Grobelny D, Poncz L, Galardy RE (1992) Inhibition of human skin fibroblast collagenase, thermolysin, and Pseudomonas aeruginosa elastase by peptide hydroxamic acids. Biochemistry 31(31):7152–7154CrossRefPubMed
23.
Prentice CR (1980) Basis of antifibrinolytic therapy. J Clin Pathol Suppl (R Coll Pathol) 14:35–40
24.
Davis GE, Saunders WB (2006) Molecular balance of capillary tube formation versus regression in wound repair: role of matrix metalloproteinases and their inhibitors. J Investig Dermatol Symp Proc 11(1):44–56CrossRefPubMed
25.
Stratman AN et al (2009) Endothelial cell lumen and vascular guidance tunnel formation requires MT1-MMP-dependent proteolysis in 3-dimensional collagen matrices. Blood 114(2):237–247CrossRefPubMed
26.
Yana I et al (2007) Crosstalk between neovessels and mural cells directs the site-specific expression of MT1-MMP to endothelial tip cells. J Cell Sci 120(Pt 9):1607–1614CrossRefPubMed
27.
Collen A et al (2003) Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood 101(5):1810–1817CrossRefPubMed
28.
Kniazeva E, Putnam AJ (2009) Endothelial cell traction and ECM density influence both capillary morphogenesis and maintenance in 3-D. Am J Physiol Cell Physiol 297(1):C179–C187CrossRefPubMed
29.
Niedbala MJ, Picarella MS (1992) Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon. Blood 79(3):678–687PubMed
30.
Kumar R et al (1998) Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 12(4):749–757PubMed
31.
Moriyama T et al (1999) Simultaneous up-regulation of urokinase-type plasminogen activator (uPA) and uPA receptor by hepatocyte growth factor/scatter factor in human glioma cells. Clin Exp Metastasis 17(10):873–879CrossRefPubMed
32.
Nishimura K et al (2003) Effects of hepatocyte growth factor on urokinase-type plasminogen activator (uPA) and uPA receptor in DU145 prostate cancer cells. Int J Androl 26(3):175–179CrossRefPubMed
33.
Lehti K et al (2005) An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature. Genes Dev 19(8):979–991CrossRefPubMed
34.
Sounni NE et al (2010) Stromal regulation of vessel stability by MMP14 and TGFbeta. Dis Model Mech 3(5–6):317–332CrossRefPubMed
35.
Baluk P et al (2009) TNF-alpha drives remodeling of blood vessels and lymphatics in sustained airway inflammation in mice. J Clin Invest 119(10):2954–2964PubMed
36.
37.
Ruoslahti E (2004) Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 32(Pt3):397–402
38.
Phelps EA et al (2010) Bioartificial matrices for therapeutic vascularization. Proc Natl Acad Sci USA 107(8):3323–3328CrossRefPubMed
39.
Moon JJ et al (2010) Biomimetic hydrogels with pro-angiogenic properties. Biomaterials 31(14):3840–3847CrossRefPubMed
40.
Aust L et al (2004) Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy 6(1):7–14CrossRefPubMed
41.
Gimble JM, Katz AJ, Bunnell BA (2007) Adipose-derived stem cells for regenerative medicine. Circ Res 100(9):1249–1260CrossRefPubMed
Metadata
Title
Mesenchymal stem cells from adipose and bone marrow promote angiogenesis via distinct cytokine and protease expression mechanisms
Authors
Suraj Kachgal
Andrew J. Putnam
Publication date
01-03-2011
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 1/2011
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-010-9194-9

Other articles of this Issue 1/2011

Angiogenesis 1/2011 Go to the issue

Original Paper

Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension

Original Paper

Vascular endothelial growth inhibitor (VEGI; TNFSF15) inhibits bone marrow-derived endothelial progenitor cell incorporation into Lewis lung carcinoma tumors

Original Paper

SR16388: a steroidal antiangiogenic agent with potent inhibitory effect on tumor growth in vivo

Abstract

Meeting abstracts of the 4th international meeting on angiogenesis

Original Paper

RETRACTED ARTICLE: Gold nanoparticles inhibit vascular endothelial growth factor-induced angiogenesis and vascular permeability via Src dependent pathway in retinal endothelial cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits